Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Novonesis Plant Biosolutions A/S has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and distinct art units. DANIELLE D JOHNSON is the busiest examiner for the portfolio, with 1 pending office action. The use of distinct art units for the 2 pending actions shows that each matter is being examined in a different technical environment. Practitioners should be prepared for independent prosecution paths for these matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, DANIELLE D | 1 | 45.0% | +13.2% |
| ROSENTHAL, ANDREW S | 1 | 51.9% | +39.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19032744 | AQUEOUS COMPOSITIONS COMPRISING SOLUBILZED LIPO-CHITOOLIGOSACCHARIDES | JOHNSON, DANIELLE D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19032744 | AQUEOUS COMPOSITIONS COMPRISING SOLUBILZED LIPO-CHITOOLIGOSACCHARIDES | JOHNSON, DANIELLE D | — |
| 18939930 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | ROSENTHAL, ANDREW S | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19032744 | AQUEOUS COMPOSITIONS COMPRISING SOLUBILZED LIPO-CHITOOLIGOSACCHARIDES | JOHNSON, DANIELLE D | 1617 | §103§112Other | Non-Final OA | — | Pending | Jan 21, 2025 |
| 18939930 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | ROSENTHAL, ANDREW S | 1613 | §103 | Non-Final OA | — | Pending | Nov 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovonesis Plant Biosolutions A/S has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Danielle D Johnson has the most, with 1 of Novonesis Plant Biosolutions A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
